Publicly traded company on the OTC Market Halberd Corp (OTCMKTS:HALB) on August 30, 2021, gave an update on the Alzheimer’s Disease eradication experimentation. The experimentation is being conducted at Youngstown State University as well as Arizona State University.
The company did two rounds on Phosphorylated Tau and its results were astonishing ensuring that researchers are looking to do more tests before publishing in scientific journals. Halberd confirmed that bodily fluids treated with nanoparticles conjoined on targeting antigens subjected to laser emissive energy as well as radiofrequency waves in separate experiments.
The antigen, Phosphorylated Tau, is the first building block of neurofibrillary tangles related to the onset of Alzheimer’s Disease. William A. Hartman, Halberd Corporation’s Chairman, President & CEO said that post completion of testing, the firm’s researchers will start writing scientific articles on the results, which should happen in the next few weeks. Hartman added that the earlier testing on E. Coli also came out with robust results.
Halberd also said that Vita-Shield-Max had been shipped as the Immunity Support Nutraceutical Product can be vital in the fight against Covid-19. Hartman said that the firm will commence selling Vita Shield and also release details on the product in the near future. The firm came out with a 120-page compilation of medical articles in its support earlier.